Business Wire

Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic

Share

Ferring Pharmaceuticals today announced the presentation of four abstracts at Digestive Disease Week (DDW) 2022 that further characterize RBX2660, a potential first-in-class microbiota-based live biotherapeutic studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005036/en/

Two of these abstracts reviewed data from PUNCH™ CD clinical program and included subgroup analyses on the potential of RBX2660 to reduce CDI recurrence consistently and safely in adults regardless of their baseline characteristics.

The first abstract (RBX2660 Versus Placebo to Reduce the Recurrence of Clostridioides Difficile Infection: Subgroup Analysis; Session number 892), an oral presentation, was a subgroup analysis of integrated data from randomized participants who received one dose of blinded treatment of RBX2660 (n=221) or placebo (n=131) in the PUNCH CD2 and PUNCH CD3 trials. In the analysis, participants who received RBX2660 demonstrated greater treatment success compared to placebo (68.3% vs. 55.0%, respectively; P=0.012). Treatment success was defined as remaining recurrence-free for 8 weeks after treatment. There were no differences in treatment success observed based on age, sex, race, ethnicity, site geography, number of previous episodes of CDI recurrence, or duration of antibiotic use prior to study entry (P>0.05).

“The consistent treatment effect with RBX2660 observed in the study, regardless of risk factors associated with recurrence such as older age, female gender, antibiotic use and underlying conditions, demonstrates the potential for RBX2660 to reduce CDI recurrence in a broad patient population,”said Paul Feuerstadt, MD, FACG, AGAF, Yale University School of Medicine.“These findings - in combination with the overall RBX2660 data presented at DDW – further support the potential efficacy and safety of RBX2660 in patients with rCDI.”

The second subgroup analysis (Treatment Success of RBX2660 in Reducing Recurrent Clostridioides difficile Infection in Patients with Underlying Comorbidities; Poster number Su1600) included participants in the modified intent-to-treat study population (n=262) of the PUNCH CD3 trial who were stratified by underlying comorbidities as mild (n=107), moderate (n=71), and severe (n=84) based on baseline Charlson Comorbidity Index (CCI) scores. The CCI is comprised of a number of comorbid conditions – such as cardiovascular and cerebrovascular diseases, any type of cancer, diabetes, and liver or kidney diseases, among others – and provides an estimate for risk of long-term mortality, with severe CCI scores equating to a higher risk of death. Participants with moderate and severe CCI scores had more CDI episodes compared with those who had a mild score.

Across all CCI subgroups, participants who received RBX2660 showed greater and consistent treatment success compared to placebo. The percentage of patients achieving treatment success with RBX2660 vs. placebo, respectively, were as follows: 76.5% vs. 71.8% (mild CCI), 68.0% vs. 57.1% (moderate CCI), and 67.8% vs. 52.0% (severe CCI). The absolute difference in treatment success rates between RBX2660 and placebo increased with increasing comorbidity burden (mild, 5%; moderate, 11%; severe, 16%).

Most treatment-emergent side effects were mild or moderate regardless of underlying comorbidities. Serious adverse events were infrequent and reported in a similar percentage of participants regardless of treatment or underlying comorbidities. One participant with a severe CCI score who received RBX2660 experienced an adverse event leading to death but no deaths or serious AEs were considered related to RBX2660 or its administration.

Additional DDW 2022 Data Presentations

Additional evidence from the RBX2660 clinical development program was presented in two separate abstracts.

One abstract (Microbiome and Bile Acid Restoration was Consistent Across Three Clinical Trials of RBX2660 for Recurrent Clostridioides Difficile Infection: A Combined Analysis; Poster number Su1596), presented in a Poster of Distinction, included stool samples from people who participated in the PUNCH CD2, PUNCH CD3, and the open-label PUNCH OLS trials. The samples were analyzed to measure microbiome diversity and microbiome composition shifts from baseline up to 8 weeks after treatment. In treatment responders for all three trials, microbiome diversity and microbiome composition shifted relative to baseline, with greater shifts among the RBX2660-treated than placebo-treated responders. Specifically, RBX2660 demonstrated an increase in the relative abundance of two important classes of beneficial bacteria – Bacteroidia and Clostridia – and reduced relative abundance of classes that could be considered harmful, Gammaproteobacteria and Bacilli. In the PUNCH CD2 and CD3 trials, bile acid compositions were restored from primary predominance before to secondary bile acid predominance after treatment. This is the first and largest multi-clinical trial analysis of microbiome and metabolome changes after investigational microbiota-based treatment.

The other abstract (Time to Recurrence in Patients with Clostridioides difficile Infection Treated with Placebo or RBX2660; Poster number Su1608) from pivotal PUNCH CD3 explored the cumulative probability of CDI recurrence, defined as the number of days from study treatment to the first assessment indicating the presence of C. difficile associated diarrhea and a positive toxin test. In the trial, 35% (30/85) and 27% (47/177) of participants experienced a probability of CDI recurrence 8 weeks following blinded treatment with placebo and RBX2660, respectively. Most CDI recurrences occurred in the first two weeks following treatment – Week 1: the cumulative probability of CDI recurrence was 18% for placebo and 14% for RBX2660; Week 2: the cumulative probability of CDI recurrence was 27% for placebo and 19% for RBX2660. The time to when at least 25% of participants experienced recurrence (25th percentile of the Kaplan Meier estimate) was 14 days for placebo and 30 days for RBX2660, suggesting that recurrence occurred sooner with placebo during the first month. This finding is consistent with results observed in the PUNCH CD2 trial. RBX2660 had a lower cumulative probability of CDI recurrence at 8 weeks compared to placebo.

About C. difficile Infection

C. difficile infection (CDI) is a serious and potentially deadly disease that impacts people across the globe. The C. difficile bacterium causes debilitating symptoms such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea, and colitis (an inflammation of the colon).1 Declared a public health threat by the U.S. Centers for Disease Control and Prevention (CDC) requiring urgent and immediate action, CDI causes an estimated half a million illnesses and tens of thousands of deaths in the U.S. alone each year.1,2,3

C. difficile infection often is the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system.4,5 Up to 35% of CDI cases recur after initial diagnosis and people who have had a recurrence are at significantly higher risk of further infections.6,7,8,9 After the first recurrence, it has been estimated that up to 65% of patients may develop a subsequent recurrence.8,9

About RBX2660

RBX2660 is a potential first-in-class microbiota-based live biotherapeutic studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection after antibiotic treatment. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome data collected over six controlled clinical trials with more than 1,000 participants.

About the PUNCH™ CD3 Clinical Trial (Clinicaltrials.gov identifier: NCT03244644)

PUNCH CD3 is a Phase 3, prospective, multi-center, randomized, double-blinded, placebo-controlled clinical trial evaluating the efficacy and safety of RBX2660 vs. placebo in preventing rCDI. The study included adults ages 18 or older who had at least one recurrence after a primary episode of CDI. Participants were followed up to 8 weeks for the efficacy analysis, and up to six months for the safety analysis. The TEAEs were mild-to-moderate GI symptoms in both the RBX2660 and placebo treated arms.

About the PUNCH™ CD2 Clinical Trial (Clinicaltrials.gov identifier: NCT02299570)

PUNCH CD2 is a Phase 2b, randomized, double-blind, placebo-controlled trial, with data indicating the drug was well-tolerated and demonstrated statistically significant treatment efficacy. The study included adults ages 18 or older who had at least two recurrences of CDI after a primary episode or had completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization. Participants were followed up to 8 weeks for the efficacy analysis, and up to 24 months for the safety analysis.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries, and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. Connect with us on our dedicated microbiome therapeutics development channels on Twitter and LinkedIn.

About DDW

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting from May 21-24, 2022. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

References:

  1. Centers for Disease Control and Prevention. What Is C. Diff? 17 Dec. 2018. Available at: https://www.cdc.gov/cdiff/what-is.html
  2. Centers for Disease Control and Prevention. Biggest Threats and Data, 14 Nov. 2019. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html
  3. Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile. Clin Microbiol Infect. 2012;18(suppl 6):2-4.
  4. Centers for Disease Control and Prevention. 24 June 2020. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf
  5. Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609.
  6. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009;23(3):727-743.
  7. Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. Published online March 11, 2021.
  8. Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012; 18 (Suppl. 6): 21–27.
  9. Smits WK, et al. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. doi: 10.1038/nrdp.2016.20.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information
Lisa Ellen
Director, Brand Communications
+1-862-286-5696 (direct)
lisa.ellen@ferring.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom